In a recent study with [18F]PSMA-1007, Luo et al. [31] reported a prevalence of focal bone uptake not classified as metastasis of only 11.6% and the presence of malignancy in 22.8% of cases when PSMA-RADS 3B (equivocal uptake in bone lesions, not defined but also not atypical of prostate cancer in anatomical imaging) [36] was used, which nevertheless exhibited a significantly lower prevalence than those reported in other studies [15,20,21,29]. The gene discussed is FOLH1; the disease is prostate carcinoma.